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AbsTrACT
background Older people experience poorer outcomes 
from colon cancer. We examined if treatment for colon 
cancer was related to age and if inequalities changed 
over time.
Methods Data from the UK population-based 
Northern and Yorkshire Cancer Registry on 31 910 
incident colon cancers (ICD10 C18) diagnosed between 
1999–2010 were obtained. Likelihood of receipt of: (1) 
cancer-directed surgery, (2) chemotherapy in surgical 
patients, (3) chemotherapy in non-surgical patients by 
age, adjusting for sex, area deprivation, cancer stage, 
comorbidity and period of diagnosis, was examined.
results Age-related inequalities in treatment exist after 
adjustment for confounding factors. Patients aged 60– 
69, 70–79 and 80+ years were significantly less likely to 
receive surgery than those aged <60 years (multivariable 
ORs (95% CI) 0.84(0.74 to 0.95), 0.54(0.48 to 0.61) and 
0.19(0.17 to 0.21), respectively). Age-related differences 
in receipt of surgery and adjuvant chemotherapy (but not 
chemotherapy in non-surgical patients) narrowed over 
time for the ’younger old’ (aged <80 years) but did not 
diminish for the oldest patients. 
Conclusions Age inequality in treatment of colon 
cancer remains after adjustment for confounders, 
suggesting age remains a major factor in treatment 
decisions. Research is needed to better understand the 
cancer treatment decision-making process, and how to 
influence this, for older patients.
InTroduCTIon
Colorectal cancer is the third most commonly diag-
nosed cancer in men and women in the UK1 and 
globally.2 Survival from colon cancer worldwide 
is worse in those aged ≥65 years,3 despite >70% 
of cases occurring in this age group.1 In addition, 
a survival deficit has been identified in the UK 
compared with countries with the highest cancer 
survival (Australia, Canada, Norway and Sweden). 
Both 1-year and 5-year survival for colorectal 
cancer are 8%–10% lower in the UK than in  coun-
tries with the highest survival, and this increases to 
a 10%–15% difference for those aged ≥65 years.3 
There is evidence that the gap in colorectal cancer 
survival between older and younger patients 
widened between 1988–1990 and 1997–1999 
across Europe in women, although narrowed slightly 
during the same time period in men.4 There was 
lower survival in the UK compared with five other 
countries with similar levels of healthcare access, 
included in the International Cancer Benchmarking 
Partnership, and this was more pronounced in older 
(aged 70–99 years) patients.5 Age-related variation 
in survival is much less marked in the USA than in 
Europe and has been attributed to earlier diagnosis 
and more aggressive treatment in the USA.6 It has 
been suggested that in several countries, including 
the UK, elderly patients with cancer are under-
treated compared with younger patients,7–9 and 
that this unequal access to treatment in practice, 
despite universal access in theory, accounts for at 
least some of the reported survival difference.5
Previous work suggests that elderly patients are 
significantly less likely to receive adjuvant therapy 
for colon cancer.10 11 It has been observed that 
elderly patients who survive 1 year after diagnosis 
of cancer have a similar 5-year prognosis to middle-
aged patients,4 suggesting that elderly patients 
who are in sufficiently good health to withstand 
treatment can derive similar benefits to younger 
patients. Determining the best course of cancer 
treatment for elderly people, a population that is 
heterogeneous in terms of health status and degree 
of frailty, is difficult for clinicians.12 Comorbidities, 
poorer health status and cancer stage at diagnosis, 
as well as patient preferences, may be valid reasons 
for not offering aggressive treatment to frail, older 
patients.13 However, many epidemiological studies 
of patterns of treatment by age fail to account for 
these factors.
A better understanding of age-related inequalities 
in treatment of colon cancer would help to inform 
interventions to improve cancer control. We under-
took a population-based study to investigate if there 
are age-related inequalities in colon cancer care in 
the North of the UK, taking into account comor-
bidity and other confounders and, if so, if these 
inequalities have changed over time.
MeThods
data sources
Data on age, sex, area deprivation (as a proxy for 
socioeconomic status (SES)), year of diagnosis, 
tumour site and stage and treatments received 
(cancer-directed surgery and chemotherapy) were 
obtained for all patients diagnosed with colon 
cancer (ICD10 C18) between 1 January 1999 and 
31 December 2010 from the population-based 
Northern and Yorkshire Cancer Registry (NYCRIS). 
NYCRIS covers a population of 6.8 million people. 
Hospitals mandatorily report cases of cancer 
directly to NYCRS. Extensive quality assurance of 
the register is performed.14 Information on treat-
ments received until 31 December 2011 was avail-
able (ie, 12 months after the latest date of diagnosis). 
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Table 1 Demographic and clinical characteristics of cohort with 
colon cancer (n=31 910)
n (%)
Age group, years
  <60 4556 (14.3) 
  60–69 7377 (23.1)
  70–79 11 086 (34.7)
  80+ 8891 (27.9)
Sex
  Female 15 212 (47.7)
  Male 16 698 (52.3)
Deprivation quintile
  1 (least deprived) 5682 (17.8)
  2 6150 (19.3)
  3 5990 (18.8)
  4 6711 (21.0)
  5 (most deprived) 7377 (23.1)
Period of diagnosis
  1999–2002 9860 (30.9)
  2003–2006 10 424 (32.7)
  2007–2010 11 626 (36.4)
Stage
  I 2782 (8.7)
  II 9107 (28.5)
  III 7738 (24.3)
  IV 7712 (24.2)
  Unstaged 4440 (13.9)
  Stage PT 131 (0.4)
CCM
  0 22 486 (70.5)
  1–2 2976 (9.3)
  3+ 700 (2.2)
  No HES link 5748 (18.0)
Treatment
  Any surgery* 24 263 (76.0)
  Surgery+chemotherapy† 7736 (31.9)
  Chemotherapy alone‡ 1589 (20.8)
  None* 6058 (19.0)
*Proportion is of all patients with colon cancer (n=31 910).
†Proportion is of all patients with colon cancer who had surgery (n=24 263).
‡Proportion is of all patients with colon cancer who did not have surgery (n=7647).
CCM, Charlson comorbidity index; HES, Hospital Episode Statistics; PT, post-treatment.
Each record was linked to UK National Health Service (NHS) 
Hospital Episode Statistics (HES) data to provide information 
on comorbidities. All admissions, outpatient appointments and 
A&E attendances at NHS hospitals in England are recorded in 
HES data. NYCRIS supplied the linked and anonymised data to 
the authors.
outcome variables
The outcome variables of interest were chosen to reflect current 
colon cancer treatment guidelines15 16: receipt of cancer-di-
rected surgery compared with no cancer-directed surgery 
(n=31 910 patients included in the analysis), receipt of chemo-
therapy in surgical patients (n=24 263), receipt of chemotherapy 
in non-surgical patients (n=7647) and receipt of no cancer-di-
rected treatment (ie, no surgery, chemotherapy or radiotherapy; 
n=31 910).
explanatory variables
Age at diagnosis was categorised into <60, 60–69, 70–79 
and 80+ years. Linearity of the relationship between age and 
outcomes was checked and it was appropriate to group age in 
this way for the analyses.
Area deprivation was measured using the rank of the income 
domain of the Index of Multiple Deprivation (IMD), grouped 
into quintiles, based on the distribution across England, with 
quintile 1 representing the most affluent areas and quintile 5 the 
highest level of deprivation.17 Year of diagnosis was categorised 
into three equal sized groups for ease of presentation and inter-
pretation: 1999–2002, 2003–2006 and 2007–2010. Cancer 
stage was assigned using the TNM staging system18 and catego-
rised as I, II, III, IV, unstaged or staged post-treatment. NYCRIS 
provided a weighted comorbidity score based on the Charlson 
comorbidity index (CCM),19 which provides a count of the 
number of relevant in-patent admissions (excluding metastatic 
cancer) recorded in HES data in the time period 3–18 months 
prior to the colon cancer diagnosis. The comorbidity score was 
categorised as 0, 1–2 or 3+ comorbid conditions resulting in an 
inpatient episode for ease of interpretation.
statistical analyses
Cases registered on the basis of a death certificate only were 
excluded (n=495). In the remaining cases, the distribution of 
receipt of cancer-directed treatment (surgery, chemotherapy in 
surgical patients, chemotherapy in non-surgical patients and no 
treatment) by age, sex, SES, period of diagnosis, stage and CCM 
was examined. As chemotherapy is not an appropriate treatment 
in early stage colon cancer, analyses were repeated, restricted to 
stage III and IV cancers.
Univariable and multivariable logistic regression models were 
used to examine the likelihood of receipt of each of the treat-
ment outcomes by age group with and without adjustment for 
covariates. Trends in likelihood of receipt of treatment by age 
over time were examined. Interaction between age and time 
period of diagnosis was tested by fitting a cross-product term 
and comparing, using the likelihood ratio test, the model with 
the cross-product term and nested model without the cross-
product term. For ease of interpretation, the results presented 
here show risk estimates for age group, stratified by period of 
diagnosis. In addition, graphs showing the marginal effects of 
the interaction terms are included as an online supplementary 
web figure.
Stata V.14.0 was used for all analyses.
resulTs
The analysis included 31 910 patients with incident colon cancer. 
There was an increase of cases over time. Almost two-thirds 
(63%) of patients were aged ≥70 years at diagnosis; a slightly 
higher proportion were men (52%) than women (table 1).
receipt of cancer-directed surgery
There was a strong inverse association between age group 
and the OR for receiving surgery which became even stronger 
after adjustment for the covariates (table 2); compared with 
the <60 years age group the multivariable ORs were 0.84, 
95% CI 0.74 to 0.95; 0.54, 0.48 to 0.61 and 0.19, 0.17 to 0.21, 
respectively (table 2). When the analyses were restricted to 
patients with stage I–III cancers, almost all (98.9%) of patients 
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Table 2 Likelihood (OR with 95% CI and p value from logistic regression) of receiving cancer-directed surgery* by age, and adjusted for sex, 
deprivation, time period, stage and comorbidity for patients with colon cancer
number (%) 
receiving surgery 
unadjusted
(n=31 910)
Mutually adjusted
(n=31 910)
n (%) or 95% CI P† values or 95% CI P† values
Age group, years <0.001 <0.001
  <60 3833 (84.1) 1.00 1.00
  60–69 6194 (84.0) 0.99 0.89 to 1.09 0.809 0.84 0.74 to 0.95 0.005
  70–79 8802 (79.4) 0.73 0.66 to 0.80 <0.001 0.54 0.48 to 0.61 <0.001
  80+ 5434 (61.1) 0.30 0.27 to 0.32 <0.001 0.19 0.17 to 0.21 <0.001
Sex <0.001 0.052
  Female 11 332 (74.5) 1.00 1.00
  Male 12 931 (77.4) 1.18 1.12 to 1.24 <0.001 1.06 0.98 to 1.14 0.160
Deprivation quintile <0.001 <0.001
  1 (least deprived) 4574 (80.5) 1.00 1.00
  2 4797 (78.0) 0.86 0.79 to 0.94 0.001 0.91 0.81 to 1.04 0.158
  3 4545 (75.9) 0.76 0.70 to 0.83 <0.001 0.76 0.67 to 0.86 <0.001
  4 5008 (74.6) 0.71 0.65 to 0.78 <0.001 0.77 0.68 to 0.87 <0.001
  5 (most deprived) 5339 (72.4) 0.63 0.58 to 0.69 <0.001 0.62 0.55 to 0.70 <0.001
Period of diagnosis <0.001 0.618
  1999–2002 7837 (79.5) 1.00 1.00
  2003–2006 7805 (74.9) 0.77 0.72 to 0.82 <0.001 0.80 0.72 to 0.87 <0.001
  2007–2010 8621 (74.2) 0.74 0.69 to 0.79 <0.001 0.93 0.84 to 1.03 0.146
Stage <0.001 <0.001
  I 2751 (98.9) 1.00 1.00
  II 9028 (99.1) 1.29 0.85 to 1.96 0.235 1.39 0.91 to 2.11 0.123
  III 7626 (98.6) 0.77 0.51 to 1.14 0.194 0.76 0.51 to 1.13 0.176
  IV 3224 (41.8) 0.01 0.01 to 0.01 <0.001 0.01 0.00 to 0.01 <0.001
  Unstaged 1506 (33.9) 0.01 0.00 to 0.01 <0.001 0.01 0.00 to 0.01 <0.001
  Stage PT 128 (97.7) 0.48 0.15 to 1.59 0.231 0.34 0.10 to 1.15 0.083
CCM <0.001 0.041
  0 17 851 (79.4) 1.00 1.00
  1–2 2156 (72.5) 0.68 0.613 to 0.74 <0.001 0.83 0. 73 to 0.95 0.007
  3+ 443 (63.3) 0.45 0.38 to 0.52 <0.001 0.68 0.54 to 0.86 0.001
  No HES link 3813 (66.3) 0.51 0.48 to 0.55 <0.001 0.71 0.64 to 0.79 <0.001
*Includes surgery +/-chemotherapy; overall 24 263 (76.0%) of 31 910 cases had surgery.
†P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P values are from a test of whether the OR is different from 1. 
CCM, Charlson comorbidity index; HES, Hospital Episode Statistics; PT, post-treatment.
received surgery. Those in the oldest age group (80+ years) 
with stage I–III cancers were significantly less likely to receive 
surgery than those in the <60 years age group (OR=0.40, 
95% CI 0.25 to 0.64). Overall, the likelihood of receiving 
surgery was lower in the two more recent time periods than 
in the period 1999–2002 but the 2006–2010 effect markedly 
attenuated after adjustment and was consistent with chance. 
There was no gender effect but patients from poorer areas 
were less likely to receive surgery. Comorbidity was associated 
with a reduced odds of surgery.
receipt of chemotherapy in surgical patients
Similar age patterns in receipt of chemotherapy were seen, 
although the gradient was even more extreme (table 3). The 
likelihood of surgical patients receiving chemotherapy increased 
over time in a dose–response pattern. Men and patients with 
higher stage cancer were more likely to get chemotherapy while 
area deprivation was associated with a reduced likelihood. When 
analyses were repeated, restricted to stage III and IV cancers, to 
take into account that chemotherapy is not appropriate for early 
stage cancers, similar results were found (data not shown).
receipt of chemotherapy in non-surgical patients
Increasing age was also strongly associated with reduced like-
lihood of receiving chemotherapy alone (OR=0. 43, 95% CI 
0.35 to 0.52; 0.20, 0.17 to 0.24 and 0.03, 0.02 to 0.04 for 
the 60–69, 70–79 and 80+ year age groups, respectively, for 
the fully adjusted model) (table 4). Other covariates showed 
the same pattern as for chemotherapy among surgical patients 
with, again, a marked period effect. Similar results were found 
when only patients with stage III and IV cancers, for whom 
chemotherapy is recommended, were included in the analysis 
(data not shown).
receipt of no treatment
Age inequalities were found in likelihood of not receiving any 
treatment (online supplementary web table 1). The OR for 
copyright.
 o
n
 17 January 2019 by guest. Protected by
http://jech.bmj.com/
J Epidem
iol Com
m
unity Health: first published as 10.1136/jech-2018-210842 on 8 November 2018. Downloaded from 
37Hayes L, et al. J Epidemiol Community Health 2019;73:34–41. doi:10.1136/jech-2018-210842
research report
Table 3 Likelihood (OR with 95% CI and p value from logistic regression) of receiving chemotherapy in surgical patients* by age, and adjusted for 
sex, deprivation, time period, stage and comorbidity for patients with colon cancer
number (%) 
receiving 
chemotherapy 
unadjusted
(n=24 263)
Mutually adjusted
(n=24 263)
n (%) or 95% CI P† values or 95% CI P† values
Age group, years <0.001 <0.001
  <60 2264 (59.1) 1.00 1.00
  60–69 2854 (46.1) 0.59 0.55 to 0.64 <0.001 0.54 0.49 to 0.60 <0.001
  70–79 2356 (26.8) 0.25 0.23 to 0.27 <0.001 0.19 0.17 to 0.21 <0.001
  80+ 262 (4.8) 0.04 0.03 to 0.04 <0.001 0.02 0.02 to 0.02 <0.001
Sex <0.001 0.126
  Female 3409 (30.1) 1.00 1.00
  Male 4327 (33.5) 1.17 1.11 to 1.23 <0.001 1.10 1.01 to 1.18 0.011
Deprivation quintile <0.001 <0.001
  1 (least deprived) 1620 (35.4) 1.00 1.00
  2 1658 (34.6) 0.96 0.88 to 1.05 0.386 1.08 0.96 to 1.20 0.201
  3 1451 (31.9) 0.86 0.78 to 0.93 <0.001 0.92 0.82 to 1.03 0.142
  4 1468 (29.3) 0.76 0.69 to 0.82 <0.001 0.81 0.72 to 0.91 <0.001
  5 (most deprived) 1539 (28.8) 0.74 0.68 to 0.80 <0.001 0.72 0.65 to 0.80 <0.001
Period of diagnosis <0.001 <0.001
  1999–2002 2235 (28.5) 1.00 1.00
  2003–2006 2515 (32.2) 1.19 1.11 to 1.28 <0.001 1.36 1.24 to 1.49 <0.001
  2007–2010 2986 (34.6) 1.33 1.24 to 1.42 <0.001 1.83 1.66 to 2.01 <0.001
Stage <0.001 <0.001
  I 39 (1.4) 1.00 1.00
  II 1442 (16.0) 13.2 9.59 to 18.2 <0.001 17.1 12.54 to 23.6 <0.001
  III 4191 (55.0) 84.8 61.7 to 116.8 <0.001 155.9 109.8 to 210.1 <0.001
  IV 1841 (57.1) 92.6 67.0 to 127.9 <0.001 137.3 98.7 to 191.0 <0.001
  Unstaged 123 (8.2) 6.18 4.29 to 8.92 <0.001 5.48 3.78 to 7.95 <0.001
  Stage PT 100 (78.1) 248.4 146.9 to 419.8 <0.001 216.0 122.5 to 380.9 <0.001
CCM 0.506 <0.001
  0 5935 (33.3) 1.00 1.00
  1–2 414 (19.2) 0.48 0.43 to 0.53 <0.001 0.53 0.46 to 0.61 <0.001
  3+ 59 (13.3) 0.31 0.23 to 0.41 <0.001 0.30 0.21 to 0.41 <0.001
  No HES link 1328 (34.8) 1.07 1.00 to 1.15 0.061 0.89 0.79 to 0.99 0.043
* Includes only patients who had surgery, n=24 263, of whom 7736 (31.9%) had chemotherapy 
† P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P values are from a test of whether the OR is different from 1. 
CCM, Charlson comorbidity index; HES, Hospital Episode Statistics; PT, post-treatment. 
receipt of no treatment in those aged 60–69 years was 1.98 
(95% CI 1.69 to 2.32) increasing to 15.4 (13.2 to 17.9) in those 
aged 80+ years, in the fully adjusted model.
Time trends in colon cancer treatment
Figure 1A shows that the difference in the ORs for receipt of 
surgery for patients aged 60–69 years and 70–79 years compared 
with those aged <60 years diminished over time. However, the 
change in the OR for patients aged 80+ years was much less 
marked (OR=0.23, 0.18 to 0.29; 0.19, 0.15 to 0.24 and 0.16, 
0.13 to 0.20 for the three time periods, respectively). Significant 
interactions were found between age and period of diagnosis for 
receipt of surgery (p=0.010) and receipt of chemotherapy in 
surgical (p=0.001), but not in non-surgical (p=0.807), patients, 
suggesting that the relationship between receipt of treatment and 
age has changed over time (online supplementary web figure).
In all time periods, surgical patients in the older age groups 
remained less likely to receive chemotherapy than those in 
the <60 years group (figure 1B). However, the difference in the 
ORs was smaller in 2007–2010 than in 1999–2002 for those in 
the 60–69 year and 70–79 year age groups. There was no change 
in the 80+ year age group. The likelihood of receiving chemo-
therapy alone remained constant within each of the age groups 
over the time periods observed (figure 1C). The likelihood of 
receiving no treatment decreased somewhat over time in the 
60–69 year age group, but increased in the 80+ year age group 
(OR=11.1, 8.3 to 14.7; 15.4, 11.9 to 20.0 and 19.2, 14.9 to 
24.7 for the three time periods, respectively) (figure 1D).
dIsCussIon
Main findings
Age inequalities in the receipt of colon cancer-directed surgery, 
chemotherapy in surgical patients and chemotherapy in non-sur-
gical patients were apparent in this population-based registry 
study, after adjustment for factors likely to be associated with 
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Table 4 Likelihood (OR with 95% CI and p value from logistic regression) of receiving chemotherapy in non-surgical patients* by age, and adjusted 
for sex, deprivation, time period, stage and comorbidity for patients with colon cancer
number (%) 
receiving 
chemotherapy 
unadjusted
(n=7647)
Mutually adjusted
(n=7647)
n (%) or 95% CI P† values or 95% CI P† values
Age group, years <0.001 <0.001
  <60 450 (62.2) 1.00 1.00
  60–69 500 (42.3) 0.44 0.37 to 0.54 <0.001 0.43 0.35 to 0.52 <0.001
  70–79 520 (22.8) 0.18 0.15 to 0.21 <0.001 0.20 0.17 to 0.24 <0.001
  80+ 119 (3.4) 0.02 0.02 to 0.03 <0.001 0.03 0.02 to 0.04 <0.001
Sex <0.001 <0.001
  Female 607 (15.6) 1.00 1.00
  Male 982 (26.1) 1.90 1.70 to 2.13 <0.001 1.40 1.22 to 1.61 <0.001
Deprivation quintile <0.001 <0.001
  1 (least deprived) 320 (28.9) 1.00 1.00
  2 304 (22.5) 0.71 0.59 to 0.86 <0.001 0.79 0.63 to 0.99 0.037
  3 316 (21.9) 0.69 0.58 to 0.83 <0.001 0.67 0.54 to 0.84 <0.001
  4 316 (18.6) 0.56 0.47 to 0.67 <0.001 0.62 0.50 to 0.78 <0.001
  5 (most deprived) 333 (16.3) 0.48 0.40 to 0.57 <0.001 0.44 0.36 to 0.55 <0.001
Period of diagnosis <0.001 <0.001
  1999–2002 331 (16.4) 1.00 1.00
  2003–2006 559 (19.8) 1.26 1.09 to 1.47 0.003 1.42 1.18 to 1.70 <0.001
  2007–2010 739 (24.6) 1.67 1.44 to 1.93 <0.001 2.42 2.01 to 2.90 <0.001
Stage <0.001 <0.001
  I 2 (6.5) 1.00 1.00
  II 9 (11.4) 1.86 0.38 to 9.16 0.443 2.15 0.41 to 11.4 0.369
  III 43 (38.4) 9.04 2.05 to 39.8 0.004 7.10 1.50 to 33.9 0.014
  IV 1406 (31.3) 6.61 1.58 to 27.8 0.100 4.20 0.94 to 18.7 0.060
  Unstaged 126 (4.3) 0.65 0.15 to 2.76 0.560 0.72 0.16 to 3.25 0.671
  Stage PT 3 (100.0) –
CCM <0.001 <0.001
  0 1172 (25.3) 1.00 1.00
  1–2 100 (12.2) 0.41 0.33 to 0.51 <0.001 0.68 0.55 to 0.87 0.002
  3+ 19 (7.4) 0.24 0.15 to 0.38 <0.001 0.30 0.18 to 0.51 <0.001
  No HES link 298 (15.4) 0.54 0.47 to 0.62 <0.001 0.60 0.50 to 0.72 <0.001
*Includes only patients who didn’t have surgery, n=7647, of whom 1589 (20.8%) had chemotherapy. 
† P values in bold are from likelihood ratio tests of the contribution of the variable to the model. Unbolded P values are from a test of whether the OR is different from 1. 
CCM, Charlson comorbidity index; HES, Hospital Episode Statistics; PT, post-treatment. 
the appropriateness of providing treatment, including stage and 
comorbidity. These differences persisted over time. We identified 
an interaction between age and time period of diagnosis associ-
ated with receipt of treatment. This suggested a narrowing of the 
treatment gap during the period 1999–2010 between those aged 
<60 years and those aged less than <80 years, but no change in 
the treatment gap between those aged <60 years and the oldest 
(aged ≥80 years and older) patients. 
strengths of this study
The strengths of this study are the use of a population-based 
registry, linked to NHS HES data. The NYCRIS has been found 
to have excellent population coverage.20 This meant we have 
robust data on cases of colon cancer, treatment received and 
information on potential confounding factors. In contrast to 
many other studies that have examined the relationship between 
age and receipt of treatment for colon cancer and failed to adjust 
for comorbidity, data on comorbidity were available for patients 
included in this study.
Weaknesses of this study
Data included in this study were from the north of England. This 
potentially reduces the generalisability of our findings to other 
settings. As is common in population-based datasets, a notable 
proportion of patients (14% overall) were unstaged. While this 
could be due to a failure by the registry to record staging informa-
tion, the low percentage of unstaged patients who were treated, 
and the increase in percentage unstaged by age (24% in the 
80+ age group compared with 8% in the youngest age group), 
suggests that it is more likely to be because these patients were 
simply too unwell to be staged. Even in this large dataset, some 
subgroups were relatively small and had few events meaning that 
the ORs were very small or large. However, we would suggest 
that the precise risk estimates are not the most important aspect 
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Figure 1 ORs (with 95% CIs) for receipt of colon cancer directed treatment by age group, over time, adjusted for sex, deprivation, stage and 
comorbidity.
of our results; rather the importance lies in the observed pattern 
of treatment receipt by age.
We had information on treatment receipt and, for chemo-
therapy and radiotherapy this is, in effect, whether an indi-
vidual started a course of treatment. A limitation is that we 
did not know whether they completed the course; some 
studies suggest that a significant proportion of patients 
cannot complete treatment due to toxicity.21 Although we 
took account of comorbidity in our analyses, the Charlson 
comorbidity index19 that we used to identify comorbidities 
captures information only on conditions that require an 
inpatient stay. It is possible, therefore, that individuals who 
had a score of zero recorded for comorbidity suffered from 
conditions that would be included in the index, but received 
all their care in primary care or as outpatients. It is also 
the case that patients with different severity of comorbid 
diseases receive the same score, making it a somewhat 
crude measure. In addition, the CCM was not designed to 
detect frailty, which is common in older individuals and is 
an important consideration when determining appropriate 
treatment for colon cancer given the physical burden asso-
ciated with cancer treatment.12 It is very likely that we have 
underestimated true levels of comorbidity in the study popu-
lation and failed to fully control for confounding by health 
status. Thus, it remains possible that the observed trends in 
treatment receipt by age could be a result, at least in part, 
of valid clinical decisions based on the patient’s overall 
health and likely ability to withstand treatment. As is usual 
with registry data, we did not have information on whether 
treatment was given with curative or palliative intent. In 
addition, patient and family preferences around quality of 
life can also influence treatment decisions and as this is not 
recorded, we were unable to take these factors into account 
in our analyses.
We note that, despite those in the oldest age group with a stage 
I–III cancer being significantly less likely to receive surgery than 
those in the youngest age group, the number in this age group 
not receiving surgery was small (n=98 patients; 2%) and this 
might be accounted for by sound clinical reasons not to offer 
surgery to these individuals.
Interpretation of findings
Age-related inequalities in the treatment of colon cancer 
have previously been reported. In particular, it has been 
noted that older people with colon cancer typically receive 
less adjuvant chemotherapy than younger individuals and 
that the likelihood of receiving adjuvant chemotherapy 
decreases with age.22 Putative reasons for this include that 
evidence for the effectiveness of adjuvant chemotherapy 
in older populations is lacking.23 More good quality trials 
of different treatment options in the elderly population 
on which evidence-based treatment decisions can be made 
are needed.10 Where trials in elderly and frail populations 
have been attempted, successes have been reported. The 
MRC FOCUS2 trial, an open factorial trial, designed to 
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examine reduced dose chemotherapy in elderly and frail 
patients (median age of 74 years) with advanced colorectal 
cancer, demonstrated that these patients can be included 
successfully in randomised controlled trials and that age and 
frailty should not preclude individuals from participation in 
research.24
Previous work has suggested that clinicians rely too much on 
chronological age rather than an assessment of biological age 
and capacity to withstand treatment when making decisions 
about how to treat patients with cancer.25 The difficulty of, 
and resources needed for, evaluating the vulnerability of elderly 
people to cancer treatment using the comprehensive geriatric 
assessment (CGA) has been acknowledged. Frailty screening 
methods to negate the need for the CGA to be used to assess all 
elderly patients have been proposed, but none has yet proved 
to be satisfactorily able to discriminate between those who are 
robust and should receive standard cancer treatment and those 
who should receive a CGA.12 Current guidance remains that 
all elderly people should receive a CGA to inform treatment 
decisions.
When we considered whether or not inequalities in receipt 
of treatment had changed over time, we found some evidence 
that the treatment gap between those aged <60 years and 
the ‘younger old’ (aged <80 years) had narrowed to some 
extent, but that there was no evidence of a narrowing of the 
treatment gap for the oldest old. This might reflect accumu-
lating trial evidence suggesting that the benefit of adjuvant 
chemotherapy is independent of age, at least up to the age 
of 79 years, but that data on the oldest old are lacking.26 In a 
pooled analysis of adjuvant chemotherapy for 3351 patients 
with resected colon cancer, 14% of included patients were 
aged 70–79 years but <1% were aged ≥80 years, leading 
the authors to conclude that extrapolation to the oldest age 
group should be made with caution.26
Within the UK, there is increasing interest in ensuring that 
the elderly receive appropriate cancer treatment. Action for the 
elderly in cancer was identified as a main priority at the Britain 
Against Cancer Conference in 2013.7 The National Cancer 
Equality Initiative, in collaboration with the Pharmaceutical 
Oncology Initiative (NCEI-POI), is a UK-wide effort to challenge 
ageism in cancer care. NCEI-POI seeks to better understand 
how treatment decisions are made in relation to cancer care for 
older people and to identify how more personalised treatment 
plans can be developed.27 It is important that the fitness of the 
individual patient, the potential benefit they might gain from 
different treatment regimens and patients’, and their family’s, 
perspectives on treatment should all be taken into account when 
designing an optimum care plan.
It was noted in a recent report published by The Royal College 
of Surgeons of England that existing national guidance does not 
make specific recommendations on how to treat older patients 
with colon cancer, and concluded that ‘all reasonable curative 
treatment options’ should be explored.28 Since it is extremely 
unlikely that the age-disparities in treatment that we have 
observed can be explained by patient or family preference, our 
data suggest that ‘all reasonable curative options’ are still not 
being explored. It should be acknowledged, however, that there 
remains a lack of good quality research into the treatment of 
elderly patients with colon cancer to inform treatment options.27 
This, together with further research to better understand the 
treatment decision-making process, and how to influence this, 
is urgently needed.
While the focus of our enquiries was on age equity, our results 
also demonstrated marked effects by area deprivation, and for 
chemotherapy, there were also gender differences. These are also 
important in terms of equitable access and appear to have inde-
pendent effects so that older women in deprived areas would be 
least likely to receive some interventions.
Colon cancer is common in older people, with 43% of cases 
diagnosed in people aged ≥75 years in the UK between 2009 and 
2011.1 Current demographic changes leading to an increasingly 
older population means the number of individuals diagnosed 
with colon cancer is likely to increase. There is a need for work 
both to identify the most effective treatment for colon cancer in 
older populations and to understand clinicians’ decision-making 
processes to ensure equitable access.
What is already known on this subject
 ► Older individuals have poorer survival from colon cancer than 
younger individuals.
 ► Inequalities in access to appropriate colon cancer treatment 
might account for this poorer survival.
What this study adds
 ► Older age is associated with lower likelihood of receiving 
colon cancer-directed surgery and adjuvant therapy, and 
greater likelihood of receiving no cancer-directed treatment, 
after adjustment for confounding factors.
 ► There is evidence that the treatment gap between 
the youngest patients and the ‘younger old’ decreased 
between 1999 and 2010.
 ► There was no narrowing of the treatment gap between the 
youngest patients and the ‘oldest old’ during this period.
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